Back to Search
Start Over
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
- Source :
- van den Bent, Martin; Eoli, Marica; Sepulveda, Juan Manuel; Smits, Marion; Walenkamp, Annemiek; Frenel, Jean-Sebastian; Franceschi, Enrico; Clement, Paul M; Chinot, Olivier; de Vos, Filip; Whenham, Nicolas; Sanghera, Paul; Weller, Michael; Dubbink, H J; French, Pim; Looman, Jim; Dey, Jyotirmoy; Krause, Scott; Ansell, Pete; Nuyens, Sarah; Spruyt, Maarten; Brilhante, Joana; Coens, Corneel; Gorlia, Thierry; Golfinopoulos, Vassilis (2021). Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 23(8):1415.
- Publication Year :
- 2021
Details
- Database :
- OAIster
- Journal :
- van den Bent, Martin; Eoli, Marica; Sepulveda, Juan Manuel; Smits, Marion; Walenkamp, Annemiek; Frenel, Jean-Sebastian; Franceschi, Enrico; Clement, Paul M; Chinot, Olivier; de Vos, Filip; Whenham, Nicolas; Sanghera, Paul; Weller, Michael; Dubbink, H J; French, Pim; Looman, Jim; Dey, Jyotirmoy; Krause, Scott; Ansell, Pete; Nuyens, Sarah; Spruyt, Maarten; Brilhante, Joana; Coens, Corneel; Gorlia, Thierry; Golfinopoulos, Vassilis (2021). Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 23(8):1415.
- Notes :
- application/pdf, info:doi/10.5167/uzh-206287, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1443039289
- Document Type :
- Electronic Resource